Êëèíè÷åñêàÿ ýôôåêòèâíîñòü êëàðèòðîìèöèíà (Êëàáàêñà) ïðè îáîñòðåíèè õðîíè÷åñêîé îáñòðóêòèâíîé áîëåçíè ëåãêèõ è åãî âëèÿíèå íà öèòîáèîõèìè÷åñêèå ìàðêåðû âîñïàëåíèÿ

The study included 49 patients men with COPD stage I-II in acute type-I. Treatment of clarithromycin compared with amoxicillin/clavulanate signifi cantly decreased sputum production, lung ventilation improves — FEV1, FVC. It was shown clinical effi cacy of clarithromycin (klabax) for the relief of exacerbations, revealed the ability of clarithromycin (klabax) modulate biomarkers of infl amma-tion, which play a key role in the pathogenesis of chronical obstructive pulmonary disease. When treating patients by klabax were not observed intolerance and side effects.